Immunotherapy has changed the treatment landscape of Head and Neck cancer (HNC).
Different immune checkpoint inhibitors targeting PD-1/PD-L1 axis have been approved for …

In countries with the best cancer outcomes, approximately 60% of patients receive
radiotherapy as part of their treatment, which is one of the most cost-effective cancer …

Abstract Background and purpose The Meta-Analysis of Chemotherapy in squamous cell
Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) …

PURPOSE We performed an open-label randomized controlled phase III study comparing
treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus …

Purpose Combining cisplatin or cetuximab with radiation improves overall survival (OS) of
patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum …

Purpose We tested the efficacy and toxicity of cisplatin plus accelerated fractionation with a
concomitant boost (AFX-C) versus standard fractionation (SFX) in locally advanced head …

Background Oropharyngeal squamous-cell carcinomas caused by human papillomavirus
(HPV) are associated with favorable survival, but the independent prognostic significance of …

Purpose Risk of cancer progression is reduced for patients with human papillomavirus
(HPV)–positive oropharynx cancer (OPC) relative to HPV-negative OPC, but it is unknown …

BACKGROUND: To analyse the overall clinical outcome and benefits by applying protocol
based image guided adaptive brachytherapy combined with 3D conformal external beam …

INTRODUCTION: The recently updated meta-analysis of chemotherapy in head and neck
cancer (MACH-NC) demonstrated the benefit of the addition of chemotherapy in terms of …